18F-FDG 代謝顯像在非小細胞肺癌化療后疾病穩定期患者療效評估中的價值_《中國呼吸與危重監護雜志》

作者：

程騰 ¹ , 孫麗華 ¹ , 王峰 ² , 谷偉 ¹ , 譚焰 ¹

1 南京醫科大學附屬南京醫院/南京市第一醫院呼吸科( 江蘇南京210006);;
2 南京醫科大學附屬南京醫院/ 南京市第一醫院核醫學科( 江蘇南京210006) 通信作者: 孫麗華, E-mail: nfhsun@ sina. com;

關鍵詞：

非小細胞肺癌脫氧葡萄糖代謝顯像疾病穩定期療效評估

DOI：

DOI: 10 . 7507 /1671 -6205 . 20130111

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的探討18 F標記的脫氧葡萄糖( 18F-FDG) 代謝顯像在非小細胞肺癌疾病穩定期患者化療療效評估中的價值。
方法回顧性分析28 例非小細胞肺癌穩定期患者化療前后18 F-FDG 代謝顯像的靶/ 非靶攝取值變化率( ΔT/N) , 并隨訪3 ～12 個月得到無進展生存期( PFS) , 分析ΔT/N與PFS 之間的相關性。根據ΔT/N不同將患者分為代謝減少組、代謝無減少組, 比較兩組患者PFS 之間差異。
結果非小細胞肺癌穩定期患者化療后ΔT/N與PFS 之間呈正相關( r = 0. 668, P lt; 0. 01) , 代謝減少組PFS 較代謝無明顯減少組PFS 顯著延長[ ( 8. 0 ±2. 5) 個月比( 5. 3 ±1. 2) 個月, P lt;0. 05] 。
結論非小細胞肺癌穩定期患者化療后ΔT/N值的不同可預示PFS的差異。

引用本文： 程騰 ,孫麗華,王峰,谷偉,譚焰. 18F-FDG 代謝顯像在非小細胞肺癌化療后疾病穩定期患者療效評估中的價值. 中國呼吸與危重監護雜志, 2013, 12(5): 461-464. doi: DOI: 10 . 7507 /1671 -6205 . 20130111 復制

1.	Steinert HC. PET and PET-CT of lung cancer. Methods Mol Biol,2011, 727: 33-51.
2.	賴燦, 楊建偉, 張江靈, 等. 探討18 F-FDG SPECT-CT 在胃癌療效評價中的價值. 腫瘤防治研究, 2010 , 37: 679-682.
3.	Festuccia C, Gravina GL, Millimaggi D, et al. Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib inprostate cancer cells. Oncol Rep, 2007 , 18: 503-511.
4.	Ceresoli GL, Gregorc V, Cordio S, et al. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced nonsmall cell lung cancer. Lung Cancer, 2004, 44: 231-239.
5.	Behzadi A, Ung Y, Lowe V, et al. The role of positron emission tomography in the management of non-small cell lung cancer. Can J Surg, 2009, 52: 235-242.
6.	Kong FM, Frey KA, Quint LE, et al. A pilot study of [ 18 F] fluoro deoxy glucose positron emission tomography scans during and after radiation-based therapy in patients with non-small-cell lung cancer.J Clin Oncol, 2007, 25 : 3116-3123.
7.	Lee DH, Kim S, Lee H, et al. Early prediction of response to firstline therapy using integrated 18 F-FDG PET/ CT for patients with advanced metastatic non-small cell lung cancer. J Tborac Oncol,.
8.	Mudd SR, Voorbach MJ, Reuter DR, et al. FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib ( ABT-869 ) in a non-small cell lung cancerxenograft model. Cancer Chemother Pharmacol, 2012, 69: 1669 -1672.
9.	Takahashi R, Hirata H, Tachibana I, et al. Early [ 18 F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung. Clin Cancer Res, 2012, 18 : 220-228 .
10.	Nahmias C, Hannal WT, Wahl LM, et al. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18 F-FDG PET/ CT. J Nucl Med, 2007, 48: 744-751 .
11.	Richard L, Heather J, Yvette K, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solidtumors. J Nucl Med, 2009 , 50: 122S-150S.
12.	Pottgen C, Levegrum S, Theegarten D, et al. Value of 18 F -fluoro-2-deoxy-D-glucose-positron emission tomography/ computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy.Clin Cancer Res, 2006, 12: 97-106.
13.	, 4: 816-21.

1. Steinert HC. PET and PET-CT of lung cancer. Methods Mol Biol,2011, 727: 33-51.
2. 賴燦, 楊建偉, 張江靈, 等. 探討18 F-FDG SPECT-CT 在胃癌療效評價中的價值. 腫瘤防治研究, 2010 , 37: 679-682.
3. Festuccia C, Gravina GL, Millimaggi D, et al. Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib inprostate cancer cells. Oncol Rep, 2007 , 18: 503-511.
4. Ceresoli GL, Gregorc V, Cordio S, et al. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced nonsmall cell lung cancer. Lung Cancer, 2004, 44: 231-239.
5. Behzadi A, Ung Y, Lowe V, et al. The role of positron emission tomography in the management of non-small cell lung cancer. Can J Surg, 2009, 52: 235-242.
6. Kong FM, Frey KA, Quint LE, et al. A pilot study of [ 18 F] fluoro deoxy glucose positron emission tomography scans during and after radiation-based therapy in patients with non-small-cell lung cancer.J Clin Oncol, 2007, 25 : 3116-3123.
7. Lee DH, Kim S, Lee H, et al. Early prediction of response to firstline therapy using integrated 18 F-FDG PET/ CT for patients with advanced metastatic non-small cell lung cancer. J Tborac Oncol,.
8. Mudd SR, Voorbach MJ, Reuter DR, et al. FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib ( ABT-869 ) in a non-small cell lung cancerxenograft model. Cancer Chemother Pharmacol, 2012, 69: 1669 -1672.
9. Takahashi R, Hirata H, Tachibana I, et al. Early [ 18 F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung. Clin Cancer Res, 2012, 18 : 220-228 .
10. Nahmias C, Hannal WT, Wahl LM, et al. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18 F-FDG PET/ CT. J Nucl Med, 2007, 48: 744-751 .
11. Richard L, Heather J, Yvette K, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solidtumors. J Nucl Med, 2009 , 50: 122S-150S.
12. Pottgen C, Levegrum S, Theegarten D, et al. Value of 18 F -fluoro-2-deoxy-D-glucose-positron emission tomography/ computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy.Clin Cancer Res, 2006, 12: 97-106.
13. , 4: 816-21.

《中國呼吸與危重監護雜志》

18F-FDG 代謝顯像在非小細胞肺癌化療后疾病穩定期患者療效評估中的價值

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

《中國呼吸與危重監護雜志》

18F-FDG 代謝顯像在非小細胞肺癌化療后疾病穩定期患者療效評估中的價值

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料